Foley Hoag advised Alcyone Therapeutics on the deal.Alcyone Therapeutics, a Lowell, Massachusetts-based biotechnology company pioneering next-generation precision central nervous system (CNS) therapies, closed $23 million in funding…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
